secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001437749-23-024969
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra sets $10M AZSTARYS milestone for 2023; merger with Acer announced
-----------------------------------------------------------------------

- Next AZSTARYS sales milestone is $10.0M; expected to be achieved in FY 2023 per current prescription trends.
- Zevra announced merger with Acer Therapeutics; Acer will become a wholly owned subsidiary upon shareholder approval.
- Zevra hosted a conference call on Aug 31, 2023 to provide supplemental information on the merger.
- Employee communication from interim CEO Christal Mickle distributed to Acer staff on Aug 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923024969/0001437749-23-024969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923024969/zvra20230831d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-024969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer